ARTICLE | Clinical News
Phase II AC2993 results from Amylin
June 20, 2001 7:00 AM UTC
AMLN said that in a placebo-controlled Phase II trial of its AC2993 synthetic exendin-4 in patients with Type II diabetes, patients receiving AC2993 in addition to their current oral therapies showed ...